Analysis of Clinical Trial Registry of India for Evidence of Anti-Arthritic Properties of Withania somnifera (Ashwagandha)
Kanjilal S, Gupta AK, Patnaik RS, Dey A
Alternative therapies in health and medicine · 5 citations
Review labels
Neutral facts our review recorded about how this study was done. They describe method, never whether we like the result.
How it was studied
- Design
- Randomized controlled trial (indexed by PubMed)
- Studied in
- People
- Main outcome
- Health markers and function
Who paid for it
- Funding
- Funding not disclosed
Publication
- Published
- 2021-11-01 · Altern Ther Health Med · vol. 27 · issue 6 · pp. 58–66
- Publisher
- National Institutes of Health
- Cited
- 12 citations · more than 88% of similar papers · 2.3× the field average
- References
- 0 works
- Access
- Paywalled
- Research areas
- Phytochemicals and Medicinal Plants · Pharmacology and Nanomedicine Research · Andrographolide Research and Applications
- Keywords
- Withania somnifera, Medicine, Clinical trial, Placebo, Arthritis, Traditional medicine, Alternative medicine, Randomized controlled trial, Physical therapy, Surgery, Internal medicine, Pathology
- MeSH
- humans, withania, plant extracts, registries, retrospective studies, india
4 authors
- Satyajyoti Kanjilal
- Ashok Kumar Gupta
- Ranjana Saksena Patnaik
- Amitabha Dey
Abstract
Background
Withania somnifera (Ashwagandha) is an herb with anti-inflammatory properties used in managing arthritis. There is significant clinical data in the public domain on the effects of Ashwagandha and this study was aimed at compiling and analysing these data in a structured manner. The major sources of evidence data were clinical trials and systematic review of extant literature.
Methodology
Retrospective database search was conducted in the Clinical Trial Registry of India for trials registered from April 2008 to March 2020, and published literature related to the anti-arthritic effects of Withania somnifera were reviewed.
Results
In all, 77 registered clinical trials were analysed and common among them were interventional, single-centre, randomized, double-blind, two-arm studies with Placebo being the comparator. Similar findings were observed in the 10 published clinical trials on arthritis evaluated for this study. While industry- and government-sponsored trials were identified, government funded sites with approvals from Institutional Ethics Committees were preferred. Most trials were registered as Phase 2 with the highest number of sites in the state of Maharashtra. The solid dosage form was most preferred.
Conclusion
While the effects of Withania somnifera on various disorders are being investigated by several clinical trials, the ones evaluated for this study provide insight on its potential in managing arthritis when given for a specific duration. Evidence shows a dosage of 6 gm in powder form or extracts in tablets, or 500 -1000 mg capsule consumed for a duration of 8 - 12 weeks may be useful in managing symptoms of arthritis in patients.
Abstract via Europe PMC. Copyright remains with the authors or publisher.
Community trust
Loading…
How much do you trust this study's findings?
Comments
Sign in to rate, comment on or flag this study.Sign inSomething wrong here?
Flag this study if its information, labels or funding look wrong. An editor reviews every flag.
Sign in to rate, comment on or flag this study.Sign inEducational information about published research. Not medical advice, and not a recommendation to start or stop anything.